The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...
